U.S. Markets closed

Did Denali Therapeutics's (NASDAQ:DNLI) Share Price Deserve to Gain 26%?

Simply Wall St

Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card!

If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly boost your returns by picking above-average stocks. For example, the Denali Therapeutics Inc. (NASDAQ:DNLI) share price is up 26% in the last year, clearly besting than the market return of around 9.4% (not including dividends). So that should have shareholders smiling. We'll need to follow Denali Therapeutics for a while to get a better sense of its share price trend, since it hasn't been listed for particularly long.

Check out our latest analysis for Denali Therapeutics

Denali Therapeutics isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.


You can see how revenue and earnings have changed over time in the image below, (click on the chart to see cashflow).

NasdaqGS:DNLI Income Statement, April 2nd 2019

We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. So we recommend checking out this free report showing consensus forecasts

A Different Perspective

It's nice to see that Denali Therapeutics shareholders have gained 26% over the last year. A substantial portion of that gain has come in the last three months, with the stock up 25% in that time. Demand for the stock from multiple parties is pushing the price higher; it could be that word is getting out about its virtues as a business. You might want to assess this data-rich visualization of its earnings, revenue and cash flow.

But note: Denali Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.